Literature DB >> 12668581

Risk factors and treatment outcomes in osteomyelitis.

Alan D Tice1, Pamela A Hoaglund, David A Shoultz.   

Abstract

Outcome indicators of recurrence and amputation were used to evaluate risk factors and treatment choices in 454 patients with osteomyelitis who completed outpatient parenteral antimicrobial therapy (OPAT). Three hundred and fifteen (69.4%) were apparently cured at the time outcomes were measured and 139 (30.6%) had a recurrence. Of the recurrences, 56% occurred within 3 months, 78% within 6 months and 95% within 1 year. Both the initial pathogen and the choice of antibiotic had an effect on the risk of treatment failure. Osteomyelitis caused by Pseudomonas aeruginosa was associated with more than a two-fold increase in recurrence (P = 0.005) compared with infection caused by Staphylococcus aureus. There was a positive correlation between P. aeruginosa and amputation. With S. aureus infections, the risk of recurrence was more than twice as great with vancomycin therapy as opposed to treatment with beta-lactams (P = 0.03). Treatment with ceftriaxone was as effective as the penicillinase-resistant penicillins and cefazolin.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12668581     DOI: 10.1093/jac/dkg186

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  46 in total

1.  A retrospective comparison of ceftriaxone versus oxacillin for osteoarticular infections due to methicillin-susceptible Staphylococcus aureus.

Authors:  Brent W Wieland; Jodie R Marcantoni; Kerry M Bommarito; David K Warren; Jonas Marschall
Journal:  Clin Infect Dis       Date:  2011-12-05       Impact factor: 9.079

2.  Ceftobiprole: First reported experience in osteomyelitis.

Authors:  A Macdonald; G Dow
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

3.  Baseline hypovitaminosis D is not associated with poor clinical outcomes in osteoarticular infections.

Authors:  J Marschall; J W S Lewis; D K Warren; H M Babcock; R L Barrack; V J Fraser
Journal:  Int J Infect Dis       Date:  2014-07-12       Impact factor: 3.623

4.  Chronic osteomyelitis.

Authors:  Ilker Uçkay; Kheeldass Jugun; Axel Gamulin; Joe Wagener; Pierre Hoffmeyer; Daniel Lew
Journal:  Curr Infect Dis Rep       Date:  2012-10       Impact factor: 3.725

5.  Bacteriophage delivering hydrogels reduce biofilm formation in vitro and infection in vivo.

Authors:  James A Wroe; Christopher T Johnson; Andrés J García
Journal:  J Biomed Mater Res A       Date:  2019-09-05       Impact factor: 4.396

6.  Antibiotic cement-coated locking plate as a temporary internal fixator for femoral osteomyelitis defects.

Authors:  Xin Yu; Hongri Wu; Jianhua Li; Zhao Xie
Journal:  Int Orthop       Date:  2016-08-13       Impact factor: 3.075

7.  Six weeks antibiotic therapy for all bone infections: results of a cohort study.

Authors:  R Farhad; P-M Roger; C Albert; C Pélligri; C Touati; P Dellamonica; C Trojani; P Boileau
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-12-10       Impact factor: 3.267

8.  Unusual manifestations of vertebral osteomyelitis: intraosseous lesions mimicking metastases.

Authors:  C Y Hsu; C W Yu; M Z Wu; B B Chen; K M Huang; T T F Shih
Journal:  AJNR Am J Neuroradiol       Date:  2008-03-20       Impact factor: 3.825

Review 9.  Optimising antimicrobial therapy in diabetic foot infections.

Authors:  Nalini Rao; Benjamin A Lipsky
Journal:  Drugs       Date:  2007       Impact factor: 9.546

10.  Outpatient parenteral antimicrobial therapy for the treatment of methicillin-susceptible Staphylococcus aureus: a comparison of cefazolin and ceftriaxone.

Authors:  S A Winans; A M Luce; R Hasbun
Journal:  Infection       Date:  2013-05-19       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.